MYC rearrangement + BCL2 rearrangement

News alerts, weekly reports and conference planners

Entrez ID:

4609; 596

Related biomarkers:

‹

›

MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3
MYC rearrangement + BCL2 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement	Lymphoma	lisocabtagene maraleucel Sensitive: C3 – Early Trials lisocabtagene maraleucel Sensitive : C3	lisocabtagene maraleucel Sensitive: C3 – Early Trials lisocabtagene maraleucel Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Non-Hodgkin’s Lymphoma	MYC rearrangement + BCL2 rearrangement	Non-Hodgkin’s Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Follicular Lymphoma	MYC rearrangement + BCL2 rearrangement	Follicular Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Follicular Lymphoma	MYC rearrangement + BCL2 rearrangement	Follicular Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	lenalidomide + zanubrutinib Sensitive: C3 – Early Trials lenalidomide + zanubrutinib Sensitive : C3	lenalidomide + zanubrutinib Sensitive: C3 – Early Trials lenalidomide + zanubrutinib Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement	Lymphoma	AR160 Sensitive: C3 – Early Trials AR160 Sensitive : C3	AR160 Sensitive: C3 – Early Trials AR160 Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	IACS-010759 Sensitive: D – Preclinical IACS-010759 Sensitive : D	IACS-010759 Sensitive: D – Preclinical IACS-010759 Sensitive : D
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	ibrutinib Resistant: D – Preclinical ibrutinib Resistant : D	ibrutinib Resistant: D – Preclinical ibrutinib Resistant : D
MYC rearrangement + BCL2 rearrangement	Non-Hodgkin’s Lymphoma	MYC rearrangement + BCL2 rearrangement	Non-Hodgkin’s Lymphoma	ibrutinib + alemtuzumab Sensitive: D – Preclinical ibrutinib + alemtuzumab Sensitive : D	ibrutinib + alemtuzumab Sensitive: D – Preclinical ibrutinib + alemtuzumab Sensitive : D
MYC rearrangement + BCL2 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement	Lymphoma	HZX-02-059 Sensitive: D – Preclinical HZX-02-059 Sensitive : D	HZX-02-059 Sensitive: D – Preclinical HZX-02-059 Sensitive : D
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	venetoclax Sensitive: D – Preclinical venetoclax Sensitive : D	venetoclax Sensitive: D – Preclinical venetoclax Sensitive : D
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	copanlisib Sensitive: D – Preclinical copanlisib Sensitive : D	copanlisib Sensitive: D – Preclinical copanlisib Sensitive : D
MYC rearrangement + BCL2 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement	Lymphoma	venetoclax + DUP 785 Sensitive: D – Preclinical venetoclax + DUP 785 Sensitive : D	venetoclax + DUP 785 Sensitive: D – Preclinical venetoclax + DUP 785 Sensitive : D
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	BTM-3566 Sensitive: D – Preclinical BTM-3566 Sensitive : D	BTM-3566 Sensitive: D – Preclinical BTM-3566 Sensitive : D
MYC rearrangement + BCL2 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement	Lymphoma	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D

MYC rearrangement + BCL2 rearrangement

Associations